Asked by: Lord Stone of Blackheath (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 21 November (HL11829), whether they plan to ask (1) the Medical Cannabis Clinicians Society, and (2) patient bodies such as the Medcan Family Foundation, to contribute to the review of the effect of the 2018 law change to allow access to unlicensed cannabis-based products for medicinal use; and what steps they are taking to ensure that that review includes consultation with scientists and patients.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
On 1 November 2018, cannabis-based products for medicinal use were placed in Schedule 2 to the Misuse of Drugs Regulations 2001. The regulations permit the prescribing of these products by, or under the direction of, specialist clinicians on the General Medical Council Specialist Register, and for use in clinical trials.
On 2 June, the Government asked the Advisory Council on the Misuse of Drugs (ACMD), a statutory independent scientific advisory body that advises the Government on drug-related issues, to review the effects of the 2018 law change. This will look at whether the changes have had the desired impact, and whether there are any unintended consequences. The ACMD is an independent scientific advisory body and determines its own procedures.
The ACMD published a public call for evidence running from 17 September 2025 to 17 October 2025, inviting submissions of evidence from all stakeholders, including, but not exclusive to, clinicians, patient bodies, scientists, and researchers. The Department alerted interested parties to the ACMD call for evidence, including the Medical Cannabis Clinicians Society, as secretariat to the All-Party Parliamentary Group on Medical Cannabis under Prescription, and patient bodies, including the Medcan Family Foundation.
Asked by: Lord Stone of Blackheath (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to transfer responsibility for policy and governance relating to cannabis-based medicinal products to the Department for Health and Social Care; and what assessment they have made of the impact of that transfer on regulatory barriers, clinical research and patient access through the NHS.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Home Office is the lead department for controlled drug legislation, whilst the Department of Health and Social Care and its Arm's Length Bodies lead on healthcare and the regulation of medicines. The Government has no plans to change this.
The Department of Health and Social Care and the Home Office work closely with other system partners in developing and reviewing policy on controlled drugs in healthcare, including cannabis-based products for medicinal use (CBPMs).
The Department of Health and Social Care and NHS England are taking an evidenced-based approach to the access of CBPMs. Since the law changed in 2018 to allow the lawful access to unlicensed CBPMs, two licensed cannabis-based medicines have been made available for prescribing on the National Health Service for patients with multiple sclerosis or hard to treat epilepsies and tuberous sclerosis, where clinically appropriate. This follows approval from the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence (NICE).
NICE has assessed the available evidence, concluding that there is a clear need for more evidence to support routine prescribing and funding decisions of unlicensed CBPMs. NHS funding decisions follow established procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.
On the 2 June, the Government asked the Advisory Council on the Misuse of Drugs (ACMD), a statutory independent scientific advisory body that advises the Government on drug-related issues, to review the effect of the 2018 law change, and to look at whether it has had the desired impact, and whether there are any unintended consequences. The Government will carefully consider the ACMD’s advice prior to making any decisions.
Asked by: Lord Stone of Blackheath (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to ensure that the cost of prescribed cannabis for medical purposes does not constitute a barrier to access for disabled people.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
There are extensive arrangements in place in England to ensure that prescriptions are affordable for everyone. Approximately 89% of prescription items are dispensed free of charge in the community in England, and there are wide range of exemptions from prescription charges already in place for which those with medical conditions may be eligible.
The Department does not make provision for the funding of medicines outside of the National Health Service’s commissioning systems and it remains that the cost of treatments sought privately are the responsibility of patients.
Pricing in the private market is a matter for individual companies and for private providers.